Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy & Immunology
Hay fever treatment shown to reduce symptoms by 37%
January 25th, 2005
According to preliminary results from a new study (GT-07), ALK-Abello's ground-breaking tablet-based allergy immunotherapy treatment reduces rhino-conjunctivitis (hay fever) symptoms by 37%, whilst reducing the need for symptom relieving medication by 41% (compared with placebo). The GT-07 study demonstrates the efficacy and confirms the favorable safety profile of the grass tablet, recently reported in the phase IIb/III trial (GT-02) - the largest allergy immunotherapy study ever performed. "These are exciting results for ALK-Abello," commented Jens Bager, CEO, ALK-Abello A/S. "This study clearly reinforces our strategy of investment in the tablet...
Source: Life Science Weekly (2005-01-25)
|
